N-tert-butyl-N-pentylamine | 4266-04-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-tert-butyl-N-pentylamine
• 英文别名: Tert-butyl-n-amyl-amine；N-tert-butylpentan-1-amine
• CAS: 4266-04-0
• 化学式: C₉H₂₁N
• 分子量: 143.272
• InChiKey: PKKKSUKYKSPFSS-UHFFFAOYSA-N

物化性质

• 沸点：
  170.1±8.0 °C(Predicted)
• 密度：
  0.770±0.06 g/cm3(Predicted)
• 保留指数：
  937

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-tert-butyl-N-pentylamine 在 copper acetylacetonate sodium tetrahydroborate 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 、 异丙醇 为溶剂， 生成 2-amino-N-tert-butyl-N-pentylbenzamide
  参考文献：
  名称：

  Radical-based methodology for efficient generation of acyclic N-acylimines

  摘要：

  alpha -Methoxybenzamides 11, which are convenient precursors of acyclic N-acylimines, can be cleanly generated in high yields via a free radical process starting from an o-aminobenzamide 16 derived from an N-t-butyl or N-cumyl secondary amine. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(00)01683-x
• 作为产物：
  描述：

  N-(tert-butyl)pentanamide 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 以579 mg的产率得到N-tert-butyl-N-pentylamine
  参考文献：
  名称：

  用三苯基膦二三氟甲磺酸酯活化，由氨基磺酸盐有效合成不对称磺酰胺

  摘要：

  描述了制备不对称磺酰胺的一般方法。该方法依赖于氨基磺酸盐被三苯基膦二三氟甲磺酸盐活化，并随后被亲核胺捕获。这种策略改善了获得ň -octadecyl- ñ '-propylsulfamide，一个摄食抑制。

  DOI：

  10.1016/j.tet.2019.02.063

文献信息

• COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES
  申请人：Arvinas, Inc.

  公开号：US20190151295A1

  公开（公告）日：2019-05-23

  The present disclosure relates to bifunctional compounds, which find utility as modulators of Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4); the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hppel-Lindau, cereblon, ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为白细胞介素-1受体相关激酶4（IRAK-4；目标蛋白）的调节剂具有实用性。具体而言，本公开涉及包含一端结合E3泛素连接酶的Von Hppel-Lindau、cereblon配体的双功能化合物，另一端结合目标蛋白的部分，使得目标蛋白靠近泛素连接酶以实现目标蛋白的降解（和抑制）。本公开展示了与目标蛋白的降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由目标蛋白聚集或积累导致的疾病或紊乱。
• SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE
  申请人：Smith D. Charles

  公开号：US20070032531A1

  公开（公告）日：2007-02-08

  The invention relates to compounds, pharmaceutical compositions thereof, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease,

  这项发明涉及化合物、其药物组合物以及抑制鞘氨醇激酶并治疗或预防过度增殖性疾病、炎症性疾病或血管生成性疾病的方法。
• PROCESS FOR THE MANUFACTURING OF BETAMIMETICS
  申请人：KRUEGER Thomas

  公开号：US20070088160A1

  公开（公告）日：2007-04-19

  The present invention relates to a process for preparing betamimetics of formula 1, wherein n denotes 1 or 2; R 1 denotes hydrogen, halogen, C 1-4 -alkyl or O—C 1-4 -alkyl; R 2 denotes hydrogen, halogen, C 1-4 -alkyl or O—C 1-4 -alkyl; R 3 denotes hydrogen, C 1-4 -alkyl, OH, halogen, O—C 1-4 -alkyl, O—C 1-4 -alkylene-COOH, O—C 1-4 -alkylene-COO—C 1-4 -alkyl.

  本发明涉及一种制备式1的β-受体激动剂的方法，其中n表示1或2；R1表示氢、卤素、C1-4-烷基或O—C1-4-烷基；R2表示氢、卤素、C1-4-烷基或O—C1-4-烷基；R3表示氢、C1-4-烷基、羟基、卤素、O—C1-4-烷基、O—C1-4-亚烷基-羧基、O—C1-4-亚烷基-COO—C1-4-烷基。
• [EN] SMALL MOLECULE VE-PTP INHIBITORS<br/>[FR] INHIBITEURS DE VE-PTP À PETITES MOLÉCULES
  申请人：RIPKA AMY

  公开号：WO2021257754A1

  公开（公告）日：2021-12-23

  The present disclosure relates to compounds capable of inhibiting vascular endothelial protein tyrosine phosphatase (VE-PTP). These compounds are also capable of activating Tie2 receptor-mediated signaling. The present disclosure also relates to pharmaceutically acceptable salts of said compounds, to pharmaceutical compositions comprising such compounds and/or pharmaceutically acceptable salts thereof, and to the use of such compounds, pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions comprising the same in treating diseases and/or conditions mediated by VE-PTP signaling, such as those mediated by Angiopoietm/Tie2 signaling.

  本公开涉及能够抑制血管内皮蛋白酪氨酸磷酸酶（VE-PTP）的化合物。这些化合物还能够激活Tie2受体介导的信号传导。本公开还涉及所述化合物的药学上可接受的盐，包括含有这些化合物和/或药学上可接受的盐的药物组合物，以及利用这些化合物、药学上可接受的盐和/或含有相同成分的药物组合物治疗由VE-PTP信号传导介导的疾病和/或病况，例如由Angiopoietm/Tie2信号传导介导的疾病。
• Novel pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
  申请人：OHGIYA Tadaaki

  公开号：US20090054474A1

  公开（公告）日：2009-02-26

  A compound represented by the following general formula (I) or a salt thereof, or a solvate thereof: (wherein R 1 , R 2 , R 3 , R 4 and R 5 are the same or different, and represent hydrogen atom, a halogen atom, a lower alkyl group etc., R 6 , R 7 and R 8 are the same or different, and represent hydrogen atom, a halogen atom, a lower alkyl group etc., R 9 and R 10 are the same or different, and represent hydrogen atom, a lower alkyl group, a (lower cycloalkyl)(lower alkyl) group etc., and R 11 represents hydrogen atom, a halogen atom, a lower alkoxy group, a (lower alkyl)thio(lower alkoxy) group, a (lower alkyl)sulfinyl(lower alkoxy) group, a (lower alkyl)sulfonyl(lower alkoxy) group etc.), which has potent inhibitory activity on CETP.

  由以下一般式（I）表示的化合物或其盐，或其溶剂合物：（其中R1、R2、R3、R4和R5相同或不同，代表氢原子、卤原子、较低烷基等，R6、R7和R8相同或不同，代表氢原子、卤原子、较低烷基等，R9和R10相同或不同，代表氢原子、较低烷基、（较低环烷基）（较低烷基）等，R11代表氢原子、卤原子、较低烷氧基、（较低烷基）硫（较低烷氧基）基、（较低烷基）亚硫基（较低烷氧基）基、（较低烷基）砜基（较低烷氧基）基等），对CETP具有强大的抑制活性。